Co-Authors
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and TIMOTHY J MCDONNELL.
Connection Strength
1.075
-
Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997 Feb; 157(2):569-74.
Score: 0.145
-
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics. 2008 Jan 31; 1:1.
Score: 0.078
-
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31.
Score: 0.073
-
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem. 2006 Sep 01; 281(35):25134-42.
Score: 0.069
-
Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol. 2005 Apr; 18(4):577-84.
Score: 0.064
-
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004 Oct 15; 10(20):6770-8.
Score: 0.062
-
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2587-93.
Score: 0.060
-
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. Oncogene. 2004 Mar 04; 23(9):1712-23.
Score: 0.059
-
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol. 2003 Apr; 169(4):1553-7.
Score: 0.055
-
TAD: a web interface and database for tissue microarrays. Appl Bioinformatics. 2002; 1(3):155-8.
Score: 0.051
-
Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction. Anticancer Res. 2001 Sep-Oct; 21(5):3141-6.
Score: 0.050
-
Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer. 2001 Jan 15; 91(2):159-66.
Score: 0.048
-
TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):1190-7.
Score: 0.045
-
Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis. 1999 Nov; 2(S3):S27.
Score: 0.044
-
Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene. 1998 Dec 03; 17(22):2889-99.
Score: 0.041
-
Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev. 1998-1999; 17(4):345-51.
Score: 0.039
-
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 Dec 15; 52(24):6940-4.
Score: 0.027
-
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20.
Score: 0.021
-
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Inform. 2007 Feb 14; 2:87-97.
Score: 0.018
-
Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702.
Score: 0.016
-
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res. 2002 Mar; 8(3):775-81.
Score: 0.013